|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A new pancreaticojejunostomy technique: A battle against postoperative pancreatic fistula显示文摘AIM:To present a new technique of end-to-side, ductto-mucosa pancreaticojejunostomy with seromuscular jejunal flap formation, and insertion of a silicone stent. METHODS:We present an end-to-side, duct-to-mucosa pancreaticojejunostomy with seromuscular jejunal flap formation, and the insertion of a silicone stent. This technique was performed in thirty-two consecutive patients who underwent a pancreaticoduodenectomy procedure by the same surgical team, from January 2005 to March 2011. The surgical procedure performed in all cases was classic pancreaticoduodenectomy, without preservation of the pylorus. The diagnosis of pancreatic leakage was defined as a drain output of any measurable volume of fluid on or after postoperative day 3 with an amylase concentration greater than three times the serum amylase activity. RESULTS:There were 32 patients who underwent end-to-side, duct-to-mucosa pancreaticojejunostomy with seromuscular jejunal flap formation. Thirteen of them were women and 19 were men. These data correspond to 40.6% and 59.4%, respectively. The mean age was 64.2 years, ranging from 55 to 82 years. The mean operative time was 310.2 ± 40.0 min, and was defined as the time period from the intubation up to the extubation of the patient. Also, the mean time needed to perform the pancreaticojejunostomy was 22.7 min, ranging from 18 to 25 min. Postoperatively, one patient developed a low output pancreatic fistula, three patients developed surgical site infection, and one patient developed pneumonia. The rate of overall morbidity was 15.6%. There was no 30-d postoperative mortality. CONCLUSION:This modification appears to be a significantly safe approach to the pancreaticojejunostomy without adversely affecting operative time. | Stylianos Katsaragakis Andreas Larentzakis Sotirios-Georgios Panousopoulos Konstantinos G Toutouzas Dimitrios Theodorou Spyridon Stergiopoulos Georgios Androulakis | 2013 | World Journal of Gastroenterology2013，19，27： | 12 |
| 2 | Molecular markers(PECAM-1,ICAM-3,HLA-DR)determine prognosis in primary non-Hodgkin's gastric lymphoma patients显示文摘瞄准:与主要 non-Hodgkin 的胃的淋巴瘤在病人调查 PECAM-1, ICAM-3 和 HLA 医生抗原的预示的意义。方法:我们免疫组织化学地在 36 个 B 房间麦芽类型主要胃的淋巴瘤病人学习了 PECAM-1, ICAM-3 和 HLA 医生抗原表示。十非恶意并且十个健康胃的织物标本被用作控制。Clinicopathological 和幸存数据与染色的结果被相关。结果:HLA 医生抗原表示在 33 个胃的淋巴瘤病人(91.7%) 和 6 个非恶意的病人(54.5%) 被检测。PECAM-1 染色了 10 个病人(27.8%) 的肿瘤房间, 9 个病人(25%) 的 endothelial 并且煽动性有良性的胃的疾病的 4 个病人(40%) 渗入。ICAM-3 表示在 17 个病人(47.2%) 的肿瘤房间上被观察,当 5 个非恶意的病人(50%) 被染色时积极也。任何一个都没为任何学习的基因健康控制被染色。在里面多,变量分析, HLA 医生抗原和 PECAM-1 被证明是与联系的统计上重要的独立预示的因素一赞成并且不利预后分别地(P=0.009 和 P=0.003 ) 。在 univariate 分析, PECAM-1 (+)/ICAM-3 (-) 和 HLA 医生(-)/ICAM-3 (-) 病人与确切相反的基因表示模式与那些相比展出了显著地减少的全面幸存(P=0.0041 和 P=0.0091,分别地) 。是 HLA 医生(+)/ICAM-3 (+)/PECAM-1 (-)(n=8 ) 的那些病人让显著地更高的幸存与这个组(n=24 )(P=0.0289 ) 的其余部分相比评价。结论:PECAM-1, ICAM-3 和 HLA 医生分别地是肿瘤扩大潜力和主人免疫者监视的代表性的标记。他们的联合使用可以帮助我们识别能得益于更好攻击的治疗学的协议的高风险的病人。 | Alexander Darom Ilias P Gomatos Emmanuel Leandros Emmu Chatzigianni Dimitris Panousopoulos Manousos M Konstadoulakis George Androulakis | 2006 | World Journal of Gastroenterology2006，12，12： | 4 |
| 3 | Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease显示文摘Treatment of inflammatory bowel disease has significantly improved since the introduction of biological agents, such as infliximab, adalimumab, certolizumab pegol, and golimumab. The Food and Drug Administration has classified these factors in category B, which means that they do not demonstrate a fetal risk. However, during pregnancy fetuses are exposed to high anti-tumor necrosis factor(TNF) levels that are measurable in their plasma after birth. Since antibodies can transfer through the placenta at the end of the second and during the third trimesters, it is important to know the safety profile of these drugs, particularly for the fetus, and whether maintaining relapse of the disease compensates for the potential risks of fetal exposure. The limited data available for the anti-TNF drugs to date have not demonstrated any significant adverse outcomes in the pregnant women who continued their therapy from conception to the first trimester of gestation. However, data suggest that antiTNFs should be discontinued during the third trimester, as they may affect the immunological system of the newborn baby. Each decision should be individualized, based on the distinct characteristics of the patient and her disease. Considering all the above, there is a need for more clinical studies regarding the effect of antiTNF therapeutic agents on pregnancy outcomes. | Ioannis Androulakis Christos Zavos Panagiotis Christopoulos George Mastorakos Maria Gazouli | 2015 | World Journal of Gastroenterology2015，21，47： | 3 |
| 4 | Photolytic degradation of all chlorophenols with polyoxometalates and H2 02 显示文摘 | Antonaraki S Androulaki E Dimotikali D | 2002 | J Photochem Photobiol : Chem2002，148，13： | 1 |
| 5 | Nanostructures boost the thermoelectric performance of PbS 显示文摘 | Johnsen S He J Q Androulakis J | 2011 | Journal of the American Chemical Society2011，133，34： | 1 |
| 6 | A genetic algorithmic framework for process design and optimization 显示文摘 | ANDROULAKIS I P VENKATASUBRAMANIAN V | 1991 | Comput Chem Engng1991，15，4： | 1 |
| 7 | Photolyfic degradation of all chlorophenols with polyoxometallates and H2O2显示文摘 | Antonaraki S Androulaki E Dimotikali D | 2002 | J Photochem Photobiol A: Chem2002，148，13： | 1 |
| 8 | A triplet combina- tion with irinotecan (CPT-ll),oxaliplatin (LOHP),continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetux- imab as first-line treatment in KRAS wt,metastatic colorectalcancer: a pilot phase II trial显示文摘 | Saridaki Z Androulakis N Vardakis N | 2012 | Br J Cancer2012，107，12： | 1 |
| 9 | Monitoring calcific aortic valve disease: the role of biomarkers 显示文摘 | LATSIOS G TOUSOULIS D ANDROULAKIS E | 2012 | Curt Med Chem2012，19，16： | 1 |
| 10 | Novel therapeutic strategies in the management of arterial hypertension 显示文摘 | Tousoulis D Androulakis E Papageorgiou N | 2012 | Pharmacol Ther2012，135，2： | 1 |
| 11 | Circulating endothelial progenitor cells as biomarkers for prediction of cardiovascular outcomes显示文摘 | Bakogiannis C Tousoulis D Androulakis E | 2012 | Curr Med Chem2012，19，16： | 1 |
| 12 | Preparation, Fractal Surface Morphology and Photocatalytic Properties of TiO2Films 显示文摘 | Androulaki E Hiskia A Falaras P | 1999 | Thin Solid Films1999，357，2： | 1 |
| 13 | CT evaluation of renal artery embolism with ectopic artery显示文摘 | Raptis L Androulaki M Passas G | 2006 | Eur J Intern Med2006，17，1： | 1 |
| 14 | Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase Ⅱ study 显示文摘 | Ziotopoulos P Androulakis N Mylonaki E | 2005 | Lung Cancer2005，50，1： | 1 |
| 15 | Endo- thelial dysfunction and atherosclerosis: focus on nov- el therapeutic approaches显示文摘 | Briasoulis A Tousoulis D Androulakis ES | 2012 | Recent Pat Cardiovasc Drug Discov2012，7，1： | 1 |
| 16 | Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor(G-CSF):a phase Ⅱ trial显示文摘 | Kourousis C Androulakis N Kalbakis K | 2000 | American Journal of Clinical Oncology2000，23，4： | 1 |
| 17 | FOLFOXIRI (folinic acid,5-fluorouracil,oxaliplatin and irinotecan) vs FOLFIRI (folinic acid,5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC):a multicentre randomised phase Ⅲ trial from the Hellenic Oncology Research Group (HORG)显示文摘 | Souglakos J Androulakis N Syrigos K | 2006 | Br J Cancer2006，94，： | 1 |
| 18 | Circulating endotheli- al progenitor cells as biomarkers for prediction of cardiovascular out- comes 显示文摘 | Bakogiannis C Tousoulis D Androulakis E | 2012 | Curr Med Chem2012，19，16： | 1 |
| 19 | Bone remodeling 显示文摘 | Hadjidakis D J Androulakis II | 2006 | Ann NY Acad Sci2006，1092，： | 1 |
| 20 | FOLFOXIRI(folinic acid,5-fluorouracil,oxaliplatin and irinotecan) VS FOLFIRI (foiinic acid,5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC):a multicentre andomised phase Ⅲtrial from the Hellenic Oncology Research Group (HORG)显示文摘 | Souglakos J Androulakis N Syrigos K | 2006 | Br J Cancer2006，94，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员